Masimo’s (MASI) Buy Rating Reaffirmed at Stifel Nicolaus

Masimo (NASDAQ:MASI)‘s stock had its “buy” rating reaffirmed by investment analysts at Stifel Nicolaus in a note issued to investors on Friday,Benzinga reports. They currently have a $190.00 price objective on the medical equipment provider’s stock, up from their prior price objective of $170.00. Stifel Nicolaus’ target price would indicate a potential upside of 9.85% from the stock’s previous close.

Several other research analysts have also weighed in on the company. Piper Sandler increased their target price on Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price for the company in a report on Wednesday, November 6th. Wells Fargo & Company raised their price target on shares of Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. BTIG Research increased their price objective on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Masimo presently has an average rating of “Moderate Buy” and a consensus target price of $167.00.

Masimo Stock Up 2.3 %

Shares of NASDAQ:MASI opened at $172.96 on Friday. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The firm has a market cap of $9.26 billion, a price-to-earnings ratio of 119.28 and a beta of 0.97. The stock’s 50-day moving average price is $143.48 and its two-hundred day moving average price is $128.00. Masimo has a 12-month low of $91.60 and a 12-month high of $174.34.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. During the same period last year, the company earned $0.63 earnings per share. The company’s quarterly revenue was up 5.4% on a year-over-year basis. On average, research analysts forecast that Masimo will post 4.04 EPS for the current year.

Institutional Investors Weigh In On Masimo

A number of large investors have recently added to or reduced their stakes in the company. NBC Securities Inc. boosted its position in Masimo by 47.1% in the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 73 shares during the last quarter. MML Investors Services LLC grew its stake in Masimo by 4.9% during the 3rd quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider’s stock valued at $274,000 after purchasing an additional 96 shares in the last quarter. Fifth Third Bancorp increased its holdings in Masimo by 16.4% during the 2nd quarter. Fifth Third Bancorp now owns 695 shares of the medical equipment provider’s stock worth $88,000 after purchasing an additional 98 shares during the last quarter. Oak Thistle LLC increased its holdings in Masimo by 5.2% during the 2nd quarter. Oak Thistle LLC now owns 2,079 shares of the medical equipment provider’s stock worth $262,000 after purchasing an additional 103 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in shares of Masimo by 75.0% in the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 111 shares in the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.